Sign in to follow this  
Followers 0
Guest Sherrill

Imatinib Mesylate Reduces Production Of Extracellular Matrix And Prevents Development Of Experimental Dermal Fibrosis

1 post in this topic

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Considering its favorable pharmacokinetics and clinical experience with its use in other diseases, imatinib mesylate is a promising candidate for the treatment of fibrotic diseases such as SSc. PubMed. Arthritis rheumatologist. 2007 Jan;56(1):9-12. (Also see: Skin Fibrosis and Scleroderma Treatments)

This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information. http://www.sclero.org/news/a-to-z.html

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!


Register a new account

Sign in

Already have an account? Sign in here.


Sign In Now
Sign in to follow this  
Followers 0